Bullfrog AI Holdings Inc. (BFRGW)

Overview

Bullfrog AI Holdings, Inc. is a pioneering digital biopharmaceutical entity entrenched in the advancement of artificial intelligence (AI) and machine learning (ML) for the purpose of delving into diverse data sets across medicine and healthcare sectors within the United States. This innovative company distinguishes itself by leveraging cutting-edge AI/ML technologies to decipher complex clinical and preclinical data, aiming to streamline and enhance the development process of medical treatments and healthcare solutions. Founded in 2017 and headquartered in Gaithersburg, Maryland, Bullfrog AI Holdings, Inc. stands at the forefront of technological integration into biopharmaceutical research and development, promising to unlock new horizons in the fight against various diseases and health conditions.

Products and Services

• bfLEAP

An advanced analytical AI/ML platform developed by Bullfrog AI Holdings, Inc., bfLEAP signifies a leap forward in the analysis of preclinical and/or clinical data. This platform is specifically designed to sift through vast datasets, identifying patterns and insights that can accelerate drug development processes, improve diagnosis, and tailor more effective treatment plans. By harnessing the power of bfLEAP, researchers and healthcare professionals can navigate the complexities of medical data more efficiently, paving the way for significant breakthroughs in medicine.

• Licensing Agreements

Bullfrog AI Holdings, Inc. has established notable licensing agreements with prestigious institutions such as George Washington University and Johns Hopkins University. These partnerships facilitate the utilization of cutting-edge treatments and formulations in tackling critical health issues:

• siRNA targeting Beta2-spectrin granted by George Washington University, focuses on the treatment of human diseases like hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
• A formulation of Mebendazole obtained from Johns Hopkins University, aimed at the treatment of glioblastoma, and various human cancer or neoplastic diseases.

These collaborations not only extend the company's research capabilities but also underscore its commitment to developing innovative healthcare solutions that can make a difference in patients' lives.